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 Abstract
Objective: The multifunctional Ca2+-binding protein S100A4 (also known as Mts1 and Fsp1) is involved in fibrosis and tissue remodeling in
several diseases including cancer, kidney fibrosis, central nervous system injury, and pulmonary vascular disease. We previously reported that
S100A4 mRNA expression was increased in hypertrophic rat hearts and that it has pro-cardiomyogenic effects in embryonic stem cell-
derived embryoid bodies. We therefore hypothesized that S100A4 could play a supportive role in the injured heart.
Methods and results: Here we verify by quantitative real-time PCR and immunoblotting that S100A4 mRNA and protein is upregulated in
hypertrophic rat and human hearts and show byway of confocalmicroscopy that S100A4protein, but notmRNA, appears in cardiacmyocytes only
in the border zone after an acute ischemic event in rat and human hearts. In normal rat and human hearts, S100A4 expression primarily colocalizes
with markers of fibroblasts. In hypertrophy elicited by aortic banding/stenosis or myocardial infarction, this expression is increased. Moreover,
invading macrophages and leucocytes stain strongly for S100A4, further increasing cardiac levels of S100A4 protein after injury. Promisingly,
recombinant S100A4 protein elicited a robust hypertrophic response and increased the number of viable cells in cardiac myocyte cultures by
inhibiting apoptosis. We also found that ERK1/2 activation was necessary for both the hypertrophy and survival effects of S100A4 in vitro.
Conclusions: Along with proposed angiogenic and cell motility stimulating effects of S100A4, these findings suggest that S100A4 can act as
a novel cardiac growth and survival factor and may have regenerative effects in injured myocardium.
© 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: S100A4/Mts1; Cardiac hypertrophy; Myocardial infarction; Cardiac myocytes; Apoptosis; Cardioprotection⁎ Corresponding author. Laboratory of Molecular Cardiology, Depart-
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0008-6363/$ - see front matter © 2007 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2007.03.027This article is referred to in the Editorial by Pleger et al.
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1. Introduction
Cardiac hypertrophy is a compensatory mechanism that
initially augments global cardiac function after biomechanical
stress, while sustained hypertrophy can lead to heart failure
and arrhythmia [1]. At the cellular level, a hypertrophic gene
program is turned on and cardiacmyocytes enlarge in responseed by Elsevier B.V. All rights reserved.
41M. Schneider et al. / Cardiovascular Research 75 (2007) 40–50
by guest on January 9, 2017
D
ow
nloaded from
 to multiple stimuli including mechanical stretch and a growing
number of biologic mediators that regulate growth, differen-
tiation and cell survival [2]. Many of these mediators are
peptides and protein growth factors that may be synthesized
within the heart in different cells, including cardiac myocytes
and fibroblasts, or may originate from inflammatory cells that
enter the heart.
We recently found increased expression of S100A4mRNA
in rat models of cardiac hypertrophy [3], and that S100A4
protein is an endogenous factor that stimulates differentiation
of embryonic stem cells into cardiac myocytes in a paracrine
fashion [4]. We therefore hypothesized that S100A4 could
play a supportive role in injured hearts.
S100A4 is an 11 kDa protein of the EF-hand containing,
Ca2+-binding S100 family that enhances metastasis of several
types of cancer cells [5]. The mechanisms of this effect are not
fully clarified, but S100A4 has both intra- and extracellular
activities. Inside the cell, S100A4 interacts with cytoskeletal
proteins involved in cell motility, such as nonmuscle myosin II
(reviewed in [6]). S100A4 also targets and regulates the
function of several intracellular signaling proteins, including
p53 [7]. As other S100 proteins, S100A4 exists as dimers and
does not possess enzymatic activity, but rather regulates the
activity of bound protein partners, likely by changing the
partners' localization or accessibility. S100A4 is secreted and
accordingly has important functions outside the cell [8,9]. Thus,
it stimulates neuronal differentiation and survival, angiogenesis,
endothelial cell motility and metalloproteinase activity, smooth
muscle cell migration and proliferation, and in vitro cardio-
myogenesis [4,8,10–14]. The molecular mechanisms whereby
S100A4 elicits these cellular responses remain elusive. It seems
that S100A4 can mediate signals via cell surface receptors [11–
14], but a specific S100A4 receptor is still to be identified.
Here, we show that S100A4 was upregulated in two rat
models of cardiac hypertrophy on both RNA and protein levels.
The S100A4 protein colocalized with markers of a variety of
interstitial cells in rat as well as human hearts, extending the
clinical importance of our findings. Quantification of immuno-
histochemical data revealed an increased S100A4 expression in
inflammatory cells of hypertrophic human hearts. Intriguingly,
in both species, cardiac myocytes were completely devoid of
S100A4 before injury; however, after acute ischemia, myocytes
in infarct border zones showedmarked S100A4 protein staining
without expressing S100A4 mRNA. We also studied the direct
effects of recombinant S100A4 protein on cultured cardiac
myocytes, and indeed observed hypertrophic growth and
survival promoting activity through a signaling pathway that
required ERK1/2 activation. These data suggest that S100A4 is
a novel cardioprotective factor that is upregulated after injury.
2. Materials and methods
2.1. Experimental animals
Methods of aortic banding (AB) and induction ofmyocardial
infarction (MI) by coronary artery occlusion in rats, is describedin [3]. The mortality rate of operated animals was∼30%within
the first 24 h; hereafter ∼16% died before analysis. The
investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
2.2. Quantitative real-time PCR
Total RNAwas isolated de novo (for each time-point: MI,
n=15; AB, n=8; sham, n=6) with TriReagent (#TR118,
Molecular ResearchCenter) after homogenizationwith aMixer
Mill 300MM(Retsch,Germany). RNAqualitywas analyzed as
previously described [15]. First-strand cDNAwas synthesized
from1μgRNAusing randomhexamer primers andOmniscript
Reverse Transcription kit (#205111, Qiagen). Q-PCR analyses
were performed with the RotorGene 3000 (Corbett Research,
Australia) and theQuantitect SYBRGreen PCR kit (Qiagen) as
described [16]. All mRNAs were quantified twice in separate
analyses. The primers used were GAPDH: 5′-
GTCGGTGTGAACGGATTTG-3′, 5′-CTTGCCGTGGGTA-
GAGTCAT-3′; S100A4: 5′-AGCTACTGACCAGG-
GAGCTG-3′, 5′-TGCAGGACAGGAAGACACAG-3′.
Results were normalized to GAPDH within the same sample.
2.3. Western blotting of S100A4 in rat hearts
Frozen left ventricles were homogenized and following
procedures were performed as previously described [17]
with use of polyclonal anti-S100A4 antibody [14]. Protein
bands were quantified by densitometry (NIH Image 1.62).
2.4. Tissue sampling
Rat tissues were sampled from frozen left ventricles of rats
subjected to AB or MI and sham operated controls. Human
left ventricular (LV) samples were collected from 4 explanted
hearts of patients undergoing orthotopic heart transplantation
due to end-stage heart disease (ischemic cardiomyopathy;
ICM). Myomectomy samples from the LV subvalvular
septum were obtained from 4 patients with aortic stenosis
(AS). Clinical data is presented in Supplementary Table 1. LV
myocardium from 3 donor hearts that for technical reasons
were not used for transplantation served as control tissues.
Tissue samples were mounted in Tissue Tec and immediately
frozen in liquid nitrogen. This investigation conforms with
the principles outlined in the Declaration of Helsinki.
2.5. Immunolabeling and confocal microscopy
Two to three samples were analyzed per subject. Frozen
sections (10 μm) were fixed 10 min with 4% paraformalde-
hyde, followed by staining procedures with primary and
secondary antibodies (listed in Supplementary Table 2). The
samples were examined by confocal microscopy (Leica TCS
SP2) and images were processed using Imaris® (Bitplane,
Switzerland) as previously described [18]. Quantification of
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 fluorescence intensity (FI) was performed as described
[18,19]. Specifically, from each optical field (250×250 μm),
5 confocal slides were obtained at 1 μm intervals. The area of
positive S100A4 labeling was defined as the number of pixels
with S100A4 signal intensity exceeding the threshold of 20 on
the 0–255 FI scale. The quantity of S100A4 per myocardial
area was expressed as the percent of myocyte surface area
occupied by S100A4 positive label. For each heart, 10–15
optical fields were analyzed. All sections were immunolabeled
simultaneously using identical dilutions of antibodies.
2.6. In situ hybridization
First strand cDNA was synthesized from total human
myocardial tissue RNA. Reverse transcription reactions were
performed using SuperscriptII (Invitrogen) and oligodT(15)
(Promega), followed by PCR reaction with 0.2 pmol of each
primer targeting S100A4 (forward: 5′-GTACGTGTT-
GATCCTGACTGCTGTCATGG-3 ′ ; reverse : 5 ′ -
TCATTTCTTCCTGGGCTGCTTATCTGGG-3′) and 5U
Taq polymerase (Eppendorf). The PCR amplified sequences
were purified, cloned into the pCRII-TOPO vector (Invitro-
gen), and sequenced. Probes were synthesized on TOPO-
S100A4 linearized with KpnI plasmid using T7 RNA
polymerase (Promega). In situ hybridization was prepared
in paraffin embedded human heart slides. Briefly, tissue
samples were hydrated with decreasing concentrations of
ethanol, fixed with 4% PFA, followed by digestion with
proteinase K and overnight hybridization with sense or
antisense S100A4 probes at 65 °C. Staining was performed
with alkaline phosphatase-conjugated anti-digoxygenin an-
tibody (1:2000; Roche) and visualized by Vector Substrate
detection Kit (Vector Laboratories).
2.7. Neonatal rat ventricular cardiac myocytes
Ventricular cardiac myocytes were prepared from 1–3 days
oldWistar rats and cultured by a protocol previously published
to yield high quality cultures [20–22]. Cardiac myocytes were
plated at 50,000–100,000 cells/cm2 depending on assay and
left untreated 48 h. L-glutamine was included in all medium
added later than 48h of culturing. ANP content of conditioned
medium was analyzed by an ANP EIA kit (EK-005-24,
Phoenix Pharmaceuticals Inc).
2.8. Immunocytochemistry
Cardiac myocytes were cultured in 2-well chamber slides
and stimulated with 0.1–100 μg/ml S100A4 or 5% fetal
bovine serum as indicated. Isolation of recombinant His-
tagged human S100A4 protein was performed as previously
described [14]. In antibody inhibition experiments, S100A4
protein and antibody were pre-incubated. Cells were fixed
after 5 days (cell size) or 30 min (S100A4 uptake) with 4%
paraformaldehyde, and stained with TRITC-labeled phalloi-
din and Sytox Green nucleic acid stain (#S7020, MolecularProbes). Cells were additionally labelled with monoclonal
anti-His antibody (1:100; #2366, Cell Signaling Technology)
and Alexa Fluor 633-conjugated anti-mouse IgG antibody
(1:100; A21050, Molecular Probes) for S100A4 uptake
analysis. Images were acquired by confocal microscopy.
Computer software (MetaMorph, Universal Imaging Corpo-
ration) was used to quantify cell size. At least 50 cells were
quantified for each treatment in each experiment.
2.9. Cell counting and PCNA Western blotting
Cardiacmyocyteswere stimulatedwith orwithout 50μg/ml
S100A4 or 5% serum. Where the MEK1/2 inhibitor U0126
(#U112A, Promega) was used, this was added 30 min prior to
stimulation. Cells were counted in a haemocytometer before
and after stimulation for 2 days; at least 200 cells were counted
in each of duplicate samples. To determine levels of pro-
liferating cell nuclear antigen (PCNA), cell lysates were sub-
jected toWestern blotting and immunolabeledwith anti-PCNA
antibody (1:2500; #610664, BD Biosciences) as previously
described [22]. Specific PCNA bands were quantified by
densitometry.
2.10. Apoptosis assays
Cardiac myocytes were plated in the presence of 5% serum
to minimize “basal” apoptosis, and mediumwas changed after
48 h. 72 h after seeding, cells were incubated 24 h in medium
without serum and with/without S100A4 (50% μg/ml).Where
indicated, doxorubicin was added 1 h after serum deprivation/
S100A4 stimulation. Quantification of DNA fragmentation
was done using the Cell death detection ELISA kit (#1774425,
Roche). To determine levels of cleaved caspase 3, cell lysates
were subjected toWestern blotting and immunolabeledwith an
antibody that recognizes cleaved as well as uncleaved caspase
3 (#9662, Cell Signaling Technology), and densities of cleaved
caspase 3 bands were quantified.
2.11. [6-3H]-thymidine incorporation
New medium with 0.2 μl [6-3H]-thymidine and different
agonists were added to cardiac myocytes 48 h after plating.
After 24 h incubation cells were fixed in 10% TCA, 30 min
at 4 °C. Cells were washed in ethanol (0 °C) before lysis in
400 μl lysisbuffer (0.1 M NaOH, 1% SDS) 20 min at room
temperature. Lysates were counted in scintillation counter.
2.12. ERK1/2-phosphorylation
Cardiac myocytes were serum starved 24 h prior to ex-
periments and treated with S100A4 (50 μg/ml) or angioten-
sin II (AngII; 100nM) for indicated times. U0126 was added
30 min before agonist. Cell lysates were subjected to
Western blotting, immunolabeled with anti-ERK1/2 and
anti-pERK1/2 (#9107 and #9101, Cell Signaling Technolo-
gy), and analyzed as described [20,21].
Fig. 1. Expression of S100A4 is increased in hypertrophic rat hearts. Rats
subjected to AB or MI were sacrificed after indicated number of weeks. The
extent of hypertrophy is presented as mean heart weight to body weight ratio
relative to sham of individual groups. S100A4 mRNA and protein levels in
left ventricles were analyzed by A, Q-PCR, normalized to GAPDH levels,
and by B, densitometric immunoblotting, respectively. Expression levels
were normalized to matching shams. In B, average values of analyzed
samples are presented along with representative blots of single samples.
Though S100A4 protein levels were markedly increased in both models and
at all time points, only levels in MI animals 9 weeks after surgery reached
significance (⁎, Pb0.05).
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 2.13. Statistical analysis
Data is expressed as means ±SE or +SE. Statistical
analysis of in vivo data was performed using factorial
ANOVA followed by a Tukey post hoc analysis of mean
differences, while analysis of in vitro data was done with
either paired student's t-test, indicated in figures by lines
connecting compared values, or one-sample t-tests compar-
ing with the value 1. Pb0.05 was accepted as significant and
is indicated with an asterisk.
3. Results
3.1. Expression levels of S100A4 are increased in hypertrophic
hearts
We previously reported in a microarray study of gene
expression profiles in four different rat models of cardiac
hypertrophy that S100A4 is part of a single common gene
program underlying hypertrophic remodeling [3]. Accord-
ingly, S100A4 expression was increased in hypertrophic left
ventricles regardless of the underlying experimental cause of
hypertrophy [3]. In a more detailed analysis, we used Q-PCR
and focused on the AB and MI models. This approach
revealed S100A4 mRNA expression levels in hypertrophic
hearts ranging from 2.5-fold to 5.6-fold compared to the
levels in hearts from corresponding sham-operated rats
(Fig. 1A). Western blotting experiments showed that the
protein level of cardiac S100A4 expression was similarly
elevated to 1.8–5.9-fold of sham in animals with hypertro-
phy elicited by either surgical procedure (Fig. 1B).
Additionally, when correlating S100A4 RNA or protein
levels to extent of hypertrophy of all hypertrophic hearts,
significant positive correlations were obtained (Spearman
r=0.2297 or 0.4153, respectively; Pb0.05 for both; data not
shown).
3.2. S100A4 protein is localized to areas of fibrosis and
inflammation as well as blood vessel cells and only found in
myocytes after injury
We next determined S100A4 localization in healthy and
hypertrophic hearts. Others have described specific fibro-
blast localization of S100A4 [23], but also localization to
endothelial cells, smooth muscle cells, various blood cells
and injured cardiac myocytes has been reported [24–31].
Accordingly, we costained rat myocardial sections with anti-
S100A4 antibodies, TRITC-conjugated phalloidin to visu-
alize f-actin in cardiac myocytes, and markers of fibroblast-
like cells (vimentin), macrophages (CD68), endothelial cells
(CD31), smooth muscle cells and myofibroblasts (α-SM
actin), or neutrophiles (CD45; Fig. 2 and Supplementary Fig.
1A–C). In sections from sham operated rats, S100A4
colocalized with all applied markers, except phalloidin,
suggesting that S100A4 is absent from cardiac myocytes. In
sections from MI and AB hearts, we observed a markedlystronger and more widespread S100A4 staining. Nonethe-
less, the colocalization patterns were similar to those in sham
operated animals. However, surprisingly, infarct border
zones showed strong S100A4 staining in cardiac myocytes.
The increased S100A4 protein staining was quantified by
measuring fluorescence intensity in sections from single MI
and AB hearts, showing approximately 4-fold higher levels
in AB and MI hearts as compared to control hearts
(Supplementary Fig. 1D, E). These data suggest that the
increased S100A4 RNA and protein levels are caused by the
large invasion of CD45 and CD68 positive cells, as well as
increased numbers of fibroblast-like, endothelial, and
smooth muscle cells, that are found in cardiac hypertrophy
due to ongoing inflammation, fibrosis, and angiogenesis.
3.3. S100A4 in human hearts
To address the clinical relevance of these immunohisto-
chemical findings, we extended the study to hearts from
humans with normal cardiac physiology and from patients
Fig. 2. S100A4 protein colocalizes with vimentin and CD68 positive cells of normal and hypertrophied rat hearts, and with cardiac myocytes of the infarct border
zone. Immunohistochemical staining of heart samples from sham operated, AB, and MI rats with antibodies against S100A4 (green) and A, vimentin or B, CD68
(both red). Analogous S100A4 and f-actin (red) costains are shown below each slide. Colocalization of S100A4 and relevant markers appear yellow. Arrows
indicate fibroblast-like cells in A, and CD68-macrophages positive for S100A4 in B. M, myocytes; BZ, infarct border zone.
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 suffering from ICM and AS. These diseases are closely
mimicked by our rat models of MI and AB, respectively.
Correspondingly, the colocalization patterns of S100A4 in
human hearts closely reproduced the rat data, and quantita-
tive immunoconfocal microscopy revealed an increase in
S100A4 protein staining levels in patient hearts to more than
3-fold the levels in normal hearts (Fig. 3 and Supplementary
Fig. 2). In addition, the overall S100A4 staining in infarct
border zones was almost twice as high as that in infarct
remote zones. At least some of this increased expressioncould be explained by a similar pattern of increased numbers
of S100A4 staining CD45- and CD68-positive cells (Fig. 3C
and D and Supplementary Fig. 2). Notably, S100A4 staining
of cardiac myocytes again appeared exclusively in the infarct
border zone of human hearts as evidenced by both phalloidin
and anti-α-actinin costaining (Fig. 3E). To determine
whether this localization was due to S100A4 expression or
uptake we performed in situ hybridization analysis targeting
S100A4 mRNA. Various interstitial cells stained positive for
S100A4 mRNA, whereas all cardiac myocytes were devoid
Fig. 3. S100A4 protein is increased in hearts of human patients suffering from aortic stenosis and ischemic cardiomyopathy. A, Immunohistochemical staining of
a normal human heart (Control) and hearts from patients suffering from AS or ICM, with antibodies against S100A4 (green) and CD68 (red). Both remote zone
(MI-RZ) and border zone (MI-BZ) areas are shown from the infarcted heart. Analogous S100A4 and f-actin (red) costains are shown below each slide.
Colocalization of S100A4 to CD68-macrophages appears yellow (arrows). B, Quantitative analysis of immunohistochemical S100A4 staining in controls, in
patients with AS, and in patients with ICM in the remote (MI-RZ) and border zone (MI-BZ) myocardium. The numbers of C, CD68-macrophages and D, CD45-
leukocytes positive for S100A4 were counted in same samples. E, Immunohistochemical staining of the border zone of a heart from a patient suffering from ICM,
with antibodies against S100A4 (green) and α-actinin (red). Analogous S100A4 and f-actin (red) costain is shown below. M, myocytes; BZ, infarct border zone.
F, Sections of infarct border zones of human hearts were processed for in situ hybridization with antisense or sense riboprobes and eosin counterstained. Bound
probes show dark brown staining. Arrows indicate S100A4 mRNA positive interstitial cells.
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46 M. Schneider et al. / Cardiovascular Research 75 (2007) 40–50of S100A4 mRNA even in the infarct border zones (Fig. 3F).
These cardiac myocytes thus uptake, or bind, S100A4
protein originating from other cells strongly suggesting a
paracrine behavior of cardiac S100A4 protein.
3.4. Recombinant S100A4 protein promotes hypertrophy
and survival of cultured cardiac myocytes
To assess the possible paracrine role of S100A4 on
cardiac myocytes we turned to in vitro studies of neonatal rat
cardiac myocytes. Notably, extracellularly applied S100A4
protein could be detected in intracellular vesicle-like
structures and nuclei of cells treated 30 min with purified
recombinant S100A4 (Fig. 4A). Treatment with S100A4
protein markedly stimulated a hypertrophic morphology of
cardiac myocytes and increased cell size in a concentration
dependent manner (Fig. 4B and C). The effect was abolishedFig. 4. Recombinant extracellular S100A4 induces hypertrophy of cardiac myocyte
S100A4, and stained for His-tagged S100A4 (blue), f-actin (red) and nuclei (green
(50 μg/ml unless otherwise indicated), and stained for f-actin and nuclei. B, Repre
with S100A4, anti-S100A4 antibody, or S100A4 pre-incubated with anti-S100A4 a
inhibition of S100A4 induced cardiac myocyte growth was quantified by morphom
experiments and is expressed as relative cell size normalized to untreated controls.
was harvested at indicated time points after stimulation with S100A4 or from contro
triplicates.by pre-incubating the protein with anti-S100A4 antibody
(Fig. 4D). S100A4 also increased ANP accumulation, a
molecular hypertrophy marker, by more than 30 fold in the
culture medium in a time dependent manner (Fig. 4E).
Next, we investigated the S100A4 effects on cardiac
myocyte numbers by counting viable cells. As depicted in
Fig. 5A, cardiac myocyte numbers were significantly higher
in the presence than in the absence of S100A4. This could be
the result of either increased survival, proliferation or a
combination of both. To address this, we first determined
possible anti-apoptotic activity. In two different assays
including DNA fragmentation ELISA and caspase 3 Western
blotting, S100A4 prominently inhibited apoptosis elicited
either by serum deprivation or by doxorubicin (Fig. 5B and
C). To determine whether S100A4 could also stimulate
cardiac myocyte proliferation, we measured the levels
of a marker of proliferation, PCNA, by densitometrics in vitro. A, Cardiac myocytes were treated 30 min with 5 μg/ml oligomeric
). B, C, and D, Cardiac myocytes were treated 5 days with S100A4 protein
sentative images of cardiac myocytes cultured in control conditions, treated
ntibody are shown. C, Concentration-response dependency and D, Antibody
etrical analysis. Data represent average values from at least three individual
E, S100A4 stimulated ANP release from cardiac myocyte cultures. Medium
l cultures (Basal). Data are representative from two experiments performed in
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Fig. 5. Cardiac myocyte viability is increased in S100A4 treated cultures by
inhibition of apoptosis. A, Viable cells were counted at the beginning of the
experiment (“Start”). Cells in remaining wells were treated with S100A4
(50 μg/ml) or serum (5%), cultured another two days, and counted (2 days).
Values represent averages of six individual experiments and are normalized
to “Start”. B and C, Apoptosis was induced by serum deprivation (-serum)
and by doxorubicin treatment (1 μM; +doxo) in the presence or absence of
S100A4 (50 μg/ml). After 24 h of incubation, B, cellular fragmented DNA
was isolated and quantified by ELISA or, C, cell lysates were immunoblotted
for caspase 3. Values are averaged from at least four independent experiments
performed in duplicate or triplicate and normalized to serum deprived control
cells. D, PCNA protein levels were quantified by densitometric Western
blotting after 48 h of treatment. Values are averaged from four independent
experiments performed in duplicates and normalized to serum treated
samples; ns, nonsignificant. E, DNA synthesis was quantified by [6-3H]-
thymidine incorporation. Cells were treated 24 h with S100A4 (50 μg/ml) or
serum (5%) in the presence of [6-3H]-thymidine. Values are averaged from
three independent experiments performed in triplicates and normalized to
control. Inserted in C and D are images of representative immunoblots.
47M. Schneider et al. / Cardiovascular Research 75 (2007) 40–50
by guest on January 9, 2017
D
ow
nloaded from
 immunoblotting (Fig. 5D), as well as DNA synthesis using a
[6-3H]-thymidine incorporation assay (Fig. 5E). Though
S100A4 did not increase PCNA levels, [6-3H]-thymidineincorporation was increased 30%, as compared to a more
than 350% increase with serum. This DNA synthesis may
therefore reflect hypertrophy-related DNA synthesis rather
than proliferation [32]. Collectively, these data suggest that
S100A4 promotes cardiac myocyte growth and survival.
3.5. S100A4 effects on cardiac myocytes are ERK1/2
dependent
The signaling processes triggering cellular effects of
S100A4 are not well understood, but at least in neurons
include the ERK1/2 MAP kinase pathway. We therefore
investigated if S100A4 protein affected ERK1/2 phosphor-
ylation state by Western blotting. This approach revealed
increased ERK1/2 phosphorylation within 3 min of S100A4
treatment and a maximal response at 30 min (Fig. 6A). In
contrast, S100A4 failed to activate two other canonical
growth and survival pathways including inositol phosphate
accumulation and Akt kinase phosphorylation (data not
shown). To ascertain the importance of the ERK cascade, we
blocked ERK1/2 activity using the MEK1/2 inhibitor
U0126. Interestingly, this abolished both cardiac myocyte
hypertrophy and pro-survival effects, suggesting ERK1/2
activation is required for S1004A stimulation of these effects
(Fig. 6B and C). In contrast, U0126 did not significantly alter
cardiac myocyte size or survival induced by 5% serum.
4. Discussion
S100A4 was first characterized as a factor promoting
metastasis (reviewed in [6]). However, today S100A4 has
several other functions ascribed, including cell motility
[8,10,12,33], neuronal differentiation [13,14,34], angiogen-
esis [8,11], and cardiomyogenesis [4]. Here, we identify
S100A4 as a member of the cardiac hypertrophy gene
program with growth and survival promoting activity on
cardiac myocytes suggesting this protein exerts a paracrine
cardioprotective effect in response to injury.
Several pieces of evidence presented in this report and
data from others support a possible paracrine function for
S100A4 in hearts. Firstly, we show that S100A4 expressing
cells, including fibroblast-like, endothelial, and inflammato-
ry cells, increase in numbers upon cardiac injury. These cell
types have been reported to release S100A4 as a paracrine
factor or passively due to cell death [9,12,24,31]. Secondly,
we present evidence that extracellular derived S100A4
protein is uptaken by cardiac myocytes and stimulates cell
growth as well as survival in myocyte cultures. Similarly,
we have previously reported that S100A4 is secreted from
parietal endoderm cells and in turn enhances cardiomyogen-
esis in embryonic stem cells [4], whereas others have
shown that release of S100A4 is promoted in pulmonary
vascular disease and in turn leads to proliferation and
migration of pulmonary artery smooth muscle cells [12,35].
Thirdly, S100A4 is known to exert effects on cell types that
participate in cardiac remodeling, including endothelial
Fig. 6. Growth and survival effects of recombinant S100A4 protein on cardiac myocytes are ERK1/2 dependent. A, Cardiac myocytes were treated with S100A4
(50 μg/ml) or AngII (100 nM) for the indicated times. Hereafter, lysates were immunoblotted for total (tERK1/2) and phosphorylated ERK1/2 (pERK1/2). Values
represent average of pERK1/2:tERK1/2 density ratios normalized to the pERK1/2:tERK1/2 ratio of AngII treated cells from at least three independent
experiments. Inserts: images of representative immunoblots. B and C, Cardiac myocytes were cultured in absence (Control) or presence (+U0126) of 10μM
U0126 and treated without (Basal) or with S100A4 (50 μg/ml) or serum (5%). In B, cell growth was quantified by morphometrical analysis after 5 days of
treatment and relative cell sizes of U0126 treated cultures were compared with that for equivalent control cultures. In C, viable cells were counted after two days
of culture. Values represent averages of at least three individual experiments and are expressed relative to untreated controls (Basal, Control).
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 cells (motility, metalloproteinase secretion and angiogenesis)
[8–11] and vascular smooth muscle cells as described above
[12]. Fourthly, S100A4 appears to be involved in the
regenerative processes of peripheral [36] and central nervous
systems [37], as it is higher expressed in astrocytes bordering
sites of neural injuries, and elicits neuronal differentiation
[13,14] and survival [34] in primary cultures of rat neurons.
The S100A4 protein in the infarct border zone myocytes is
not produced by the cardiac myocytes themselves, but must
instead be released, actively or passively, by interstitial cells and
in turn be uptaken by the myocytes. One can speculate on the
mechanisms specifically supporting uptake in infarct border
zone myocytes rendering all other myocytes free from this
extracellularly derived S100A4 protein. The receptor mediating
the binding and/or uptake of S100A4 may be induced by the
hostile milieu of the ischemic area, promoting the ability of
cardiac myocytes to respond to increased extracellular levels of
S100A4 by hypertrophic growth and survival. Moreover, given
S100A4's ability to increase cell motility and metalloproteinase
secretion, the myocytes may be partaking in tissue remodelling.
Taken together, these observations prompt speculation towards
a cardioprotective activity of S100A4, thus suggesting a parallel
supportive role of paracrine S100A4, recruited after injury, in
cardiac and neural tissue.
Our observation of increased S100A4 expression in
hypertrophic hearts is supported by the observation that
cardiac myocytes of isoproterenol treated rats are immuno-
positive for S100A4 protein [27]. However, the generalized
myocyte localization of S100A4 noted in that publication is
in sharp contrast with our observations in both our rat models
and human patients. Infarct border zones, in which we do
observe S100A4 positive myocytes is ischemic and
isoproterenol treatment probably also induces myocardial
oxygen deprivation as an effect of the strong β-adrenergic
stimulation, partially explaining this apparent discrepancy.It has been shown that paracrine S100A4 can function via
more than one cell surface receptor, possibly explaining its
many and diverse effects; but the nature of a cardiac S100A4
receptor is unknown. In all, or at least most, cases, it seems
that only oligomeric forms of S100A4 have activity on
surface receptors [4,8,13,14]. The purified recombinant
S100A4 protein used in the present study was not size
fractionated, but includes both dimeric and oligomeric
S100A4 [14]. In our initial studies of the signaling pathways
involved in S100A4 promoted growth and survival of
cardiac myocytes, we found that ERK1/2 was phosphory-
lated and that the MEK1/2–ERK1/2 pathway likely was
required for the cellular effects. These data are consistent
with observations in cultured neurons, in which neuritogenic
effects of S100A4 were also dependent on ERK1/2
activation [14]. Notably, the S100A4 induced phosphoryla-
tion of ERK1/2 was atypical with a delayed maximum
activation in both our experiments in cardiac myocytes and
in the reported experiments in neurons [14].
It is well-described that kidney fibrosis, pulmonary
fibrosis, and corneal wound healing also coincides with
high S100A4 levels, evidently owing to an increased num-
ber of activated, S100A4 expressing fibroblasts [38–40].
S100A4 may therefore have general roles in diseases
involving inflammation, fibrosis, remodeling, and/or metas-
tasis. Functions specific to cardiac disease could prove very
complex, but holds clear future clinical implication and
warrants further investigation.
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